Trials / Completed
CompletedNCT06096077
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Methodist Health System · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE is defined as physical swelling of the deep skin layers or mucous membranes due to increased vascular permeability and leakage of fluid into the interstitial space caused while taking an ACEi
Detailed description
Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE most commonly affects the lips, mouth, face, upper airway, and less commonly the gastrointestinal tract. This condition may lead to life-threatening airway compromise which would require emergent intubation. Currently, strong evidence is lacking to help guide management of ACEi-AE in the emergency department (ED).
Conditions
Timeline
- Start date
- 2022-11-30
- Primary completion
- 2023-08-23
- Completion
- 2023-08-23
- First posted
- 2023-10-23
- Last updated
- 2024-01-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06096077. Inclusion in this directory is not an endorsement.